SG11201703307WA - Therapy for inhibition of single-stranded rna virus replication - Google Patents
Therapy for inhibition of single-stranded rna virus replicationInfo
- Publication number
- SG11201703307WA SG11201703307WA SG11201703307WA SG11201703307WA SG11201703307WA SG 11201703307W A SG11201703307W A SG 11201703307WA SG 11201703307W A SG11201703307W A SG 11201703307WA SG 11201703307W A SG11201703307W A SG 11201703307WA SG 11201703307W A SG11201703307W A SG 11201703307WA
- Authority
- SG
- Singapore
- Prior art keywords
- inhibition
- therapy
- stranded rna
- rna virus
- virus replication
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201462068487P | 2014-10-24 | 2014-10-24 | |
US201462068469P | 2014-10-24 | 2014-10-24 | |
US201462068477P | 2014-10-24 | 2014-10-24 | |
US201462068492P | 2014-10-24 | 2014-10-24 | |
US201462068465P | 2014-10-24 | 2014-10-24 | |
US201562188030P | 2015-07-02 | 2015-07-02 | |
PCT/IB2015/002173 WO2016063134A1 (en) | 2014-10-24 | 2015-10-23 | Therapy for inhibition of single-stranded rna virus replication |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201703307WA true SG11201703307WA (en) | 2017-05-30 |
Family
ID=55760346
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201703307WA SG11201703307WA (en) | 2014-10-24 | 2015-10-23 | Therapy for inhibition of single-stranded rna virus replication |
Country Status (12)
Country | Link |
---|---|
US (5) | US9974800B2 (en) |
EP (2) | EP4134076A1 (en) |
JP (1) | JP6625631B2 (en) |
KR (1) | KR20170070234A (en) |
CN (2) | CN112999222B (en) |
AU (2) | AU2015334590B2 (en) |
BR (1) | BR112017008220A2 (en) |
CA (1) | CA2965258C (en) |
IL (1) | IL251847A0 (en) |
MX (1) | MX2017005350A (en) |
SG (1) | SG11201703307WA (en) |
WO (1) | WO2016063134A1 (en) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SG11201703307WA (en) * | 2014-10-24 | 2017-05-30 | Redhill Biopharma Ltd | Therapy for inhibition of single-stranded rna virus replication |
AU2016336133B2 (en) * | 2015-10-06 | 2021-02-25 | Redhill Biopharma Ltd. | Combination therapies for treating cancer |
CN108853106B (en) * | 2017-05-09 | 2021-02-02 | 中国食品药品检定研究院 | Use of imine phenazine compound as rabies virus inhibitor |
WO2019018185A1 (en) | 2017-07-15 | 2019-01-24 | Arisan Therapeutics Inc. | Enantiomerically pure adamantane derivatives for the treatment of filovirus infection |
DE102018217334A1 (en) * | 2018-10-10 | 2020-04-16 | Harbins Ruhr Bioscience, Inc. | Sphingoid base and / or active ingredient for use in the prophylaxis and / or therapy of a viral infection and / or viral infectious disease or disinfection, food / food supplements, feed / feed supplements and crop protection agents |
WO2020185637A1 (en) * | 2019-03-08 | 2020-09-17 | The Texas A&M University System | Rose rosette virus infectious clones and uses thereof |
US20210244705A1 (en) * | 2020-02-07 | 2021-08-12 | Centre For Digestive Diseases | Therapeutic compositions, products of manufacture and methods for ameliorating or preventing coronavirus infection |
MX2022011173A (en) * | 2020-03-10 | 2022-10-18 | Redhill Biopharma Ltd | Treatment of coronavirus infection. |
EP3932409A1 (en) * | 2020-06-29 | 2022-01-05 | Consejo Superior de Investigaciones Científicas (CSIC) | Compounds for the treatment and prevention of viral infections caused by coronaviruses |
EP4181906A1 (en) | 2020-07-16 | 2023-05-24 | Harbins Ruhr Bioscience, Inc. | Sphingoid compounds for use in prophylaxis and/or therapy of coronaviridae infection |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6503881B2 (en) * | 1996-08-21 | 2003-01-07 | Micrologix Biotech Inc. | Compositions and methods for treating infections using cationic peptides alone or in combination with antibiotics |
US6335339B1 (en) | 1998-01-13 | 2002-01-01 | Scriptgen Pharmaceuticals, Inc. | Triazine antiviral compounds |
SK662001A3 (en) | 1998-07-15 | 2001-10-08 | Hassan Jomaa | Phosphorous organic compounds and their use |
US7204980B2 (en) * | 2002-11-18 | 2007-04-17 | Phoenix Pharmacologics, Inc. | Methods for inhibiting viral replication in vivo |
CN101248041B (en) * | 2005-06-17 | 2013-11-20 | 艾宝奇生物工艺有限公司 | Sphingosine kinase inhibitors |
GB0803707D0 (en) * | 2008-02-28 | 2008-04-09 | Cambridge Entpr Ltd | Antiviral agent |
KR101420094B1 (en) * | 2010-10-27 | 2014-07-17 | (주)바이오니아 | Automatic realtime PCR system for the various analysis of biological sample, method for Automatic nucleic acid purification and realtime quantification of gene amplification, method for automatic viable cell count of pathogenic bacteria using realtime quantitative PCR, method for automatically getting antigene density using quantitative immunity PCR |
US9687477B2 (en) * | 2011-06-01 | 2017-06-27 | The Curators Of The University Of Missouri | Modulation of sphingosine 1-phosphate metabolizing enzymes for the treatment of negative-strand RNA virus infections |
SG11201703307WA (en) * | 2014-10-24 | 2017-05-30 | Redhill Biopharma Ltd | Therapy for inhibition of single-stranded rna virus replication |
AU2016336133B2 (en) * | 2015-10-06 | 2021-02-25 | Redhill Biopharma Ltd. | Combination therapies for treating cancer |
-
2015
- 2015-10-23 SG SG11201703307WA patent/SG11201703307WA/en unknown
- 2015-10-23 EP EP22190806.4A patent/EP4134076A1/en active Pending
- 2015-10-23 BR BR112017008220-9A patent/BR112017008220A2/en not_active Application Discontinuation
- 2015-10-23 CA CA2965258A patent/CA2965258C/en active Active
- 2015-10-23 MX MX2017005350A patent/MX2017005350A/en unknown
- 2015-10-23 JP JP2017521992A patent/JP6625631B2/en not_active Expired - Fee Related
- 2015-10-23 KR KR1020177013646A patent/KR20170070234A/en unknown
- 2015-10-23 CN CN202110229970.9A patent/CN112999222B/en active Active
- 2015-10-23 WO PCT/IB2015/002173 patent/WO2016063134A1/en active Application Filing
- 2015-10-23 EP EP15852527.9A patent/EP3209290A4/en not_active Withdrawn
- 2015-10-23 AU AU2015334590A patent/AU2015334590B2/en not_active Ceased
- 2015-10-23 US US14/921,661 patent/US9974800B2/en active Active
- 2015-10-23 CN CN201580071321.3A patent/CN107106525B/en not_active Expired - Fee Related
-
2017
- 2017-04-23 IL IL251847A patent/IL251847A0/en unknown
-
2018
- 2018-05-02 US US15/969,526 patent/US10543222B2/en active Active
-
2019
- 2019-11-27 AU AU2019271958A patent/AU2019271958B2/en not_active Ceased
-
2020
- 2020-01-24 US US16/751,931 patent/US11090325B2/en active Active
-
2021
- 2021-08-13 US US17/401,950 patent/US11786541B2/en active Active
-
2023
- 2023-09-12 US US18/465,722 patent/US20240108643A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
JP6625631B2 (en) | 2019-12-25 |
CA2965258C (en) | 2023-09-19 |
US9974800B2 (en) | 2018-05-22 |
KR20170070234A (en) | 2017-06-21 |
CN112999222B (en) | 2024-05-28 |
CN107106525B (en) | 2021-03-19 |
BR112017008220A2 (en) | 2018-01-09 |
CN112999222A (en) | 2021-06-22 |
EP3209290A1 (en) | 2017-08-30 |
AU2019271958A1 (en) | 2019-12-19 |
IL251847A0 (en) | 2017-06-29 |
US20180318328A1 (en) | 2018-11-08 |
MX2017005350A (en) | 2017-08-15 |
AU2015334590B2 (en) | 2019-08-29 |
EP3209290A4 (en) | 2018-11-14 |
WO2016063134A1 (en) | 2016-04-28 |
US20240108643A1 (en) | 2024-04-04 |
AU2019271958B2 (en) | 2020-03-05 |
US11786541B2 (en) | 2023-10-17 |
CA2965258A1 (en) | 2016-04-28 |
JP2017531673A (en) | 2017-10-26 |
EP4134076A1 (en) | 2023-02-15 |
US10543222B2 (en) | 2020-01-28 |
US20210369754A1 (en) | 2021-12-02 |
AU2015334590A1 (en) | 2017-05-18 |
US11090325B2 (en) | 2021-08-17 |
US20200155585A1 (en) | 2020-05-21 |
US20160113954A1 (en) | 2016-04-28 |
CN107106525A (en) | 2017-08-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL251847A0 (en) | Therapy for inhibition of single-stranded rna virus replication | |
HK1225968A1 (en) | Combination therapy for treatment of hbv infections | |
IL253945A0 (en) | Kdm1a inhibitors for the treatment of disease | |
IL247973A0 (en) | Methods for purification of messenger rna | |
SG11201707663SA (en) | Lyophilization of rna | |
PT3212233T (en) | Combination therapy for treatment of disease | |
SG11201701723XA (en) | Methods of treating liver disease | |
GB201701673D0 (en) | Methods of well treatment | |
PT3286166T (en) | Inhibitors of human immunodeficiency virus replication | |
IL247364A0 (en) | Inhibitors of c5a for the treatment of viral pneumonia | |
HK1225617A1 (en) | 4’-difluoromethyl substituted nucleoside derivatives as inhibitors of influenza rna replication | |
HK1251166A1 (en) | Targeted treatment of leiomyosarcoma | |
ZA201700183B (en) | Acetylcholinesterase inhibitors for treatment of dermatological conditions | |
HK1232220A1 (en) | Derivatives of 5-benzylisoquinoline for the treatment of cardiovascular diseases 5- | |
HUE049600T2 (en) | Gls1 inhibitors for treating diseases | |
HK1258994A1 (en) | Methods for treatment of diseases | |
HK1252245A1 (en) | Nucleotides for the treatment of cancer | |
GB201416832D0 (en) | Methods of treatment | |
PT3107913T (en) | Inhibitors of human immunodeficiency virus replication | |
PT3105236T (en) | Benzothiazole macrocycles as inhibitors of human immunodeficiency virus replication | |
GB201412010D0 (en) | Treatment of hypertransaminasemia | |
SG11201703330YA (en) | Iminosugars useful for the treatment of viral diseases | |
GB201403369D0 (en) | RNA Virus induced gene expression | |
GB201421812D0 (en) | New therapeutic uses of enzyme inhibitors | |
GB201410529D0 (en) | New therapeutic uses of enzyme inhibitors |